- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 02.07. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 01.07. | Creative Medical gibt Update zur Geschäftsentwicklung: Fortschritte bei Zelltherapie und Biodefense-Programmen | 1 | Investing.com Deutsch | ||
| 01.07. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Issues Mid-Year Update | 297 | GlobeNewswire (Europe) | PHOENIX, July 01, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 30.06. | Creative Medical secures $4.5M through warrant exercise deal | 1 | Investing.com | ||
| CREATIVE MEDICAL TECHNOLOGY Aktie jetzt für 0€ handeln | |||||
| 30.06. | Creative Medical sichert sich 4,5 Mio. US-Dollar durch Vereinbarung zur Optionsschein-Ausübung | 2 | Investing.com Deutsch | ||
| 30.06. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Announces Agreements for Exercise of Warrants for $4.5 Million Gross Proceeds | 1 | GlobeNewswire (USA) | ||
| 25.06. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - S-1, General form for registration of securities | 1 | SEC Filings | ||
| 22.06. | FDA genehmigt Studienerweiterung für Rückenschmerztherapie von Creative Medical | 3 | Investing.com Deutsch | ||
| 22.06. | FDA clears Creative Medical trial expansion for back pain therapy | 1 | Investing.com | ||
| 22.06. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Expands ADAPT Trial Under New FDA Clearance and Rapidly Advances Toward Phase 3 Planning for Olastrocel in Chronic Lower Back Pain | 262 | GlobeNewswire (Europe) | PHOENIX, June 22, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 16.06. | Creative Medical Technology Holdings, Inc. Advances Project PHOENIX into Nationwide AI Driven Virtual Data Collection Phase for U.S. Veterans Exposed to Burn Pits and Toxic Hazards | 1 | GlobeNewswire (USA) | ||
| 08.05. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 28.04. | Creative Medical Technology Holdings, Inc. Reports Breakthrough 93% Response Rate in Ultrasome Knee Osteoarthritis Program, Expanding CELZ-201 Platform into Scalable Cell-Free Regenerative Therapies | 1 | GlobeNewswire (USA) | ||
| 24.04. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K/A, Annual Report | - | SEC Filings | ||
| 20.03. | CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. - 10-K, Annual Report | 2 | SEC Filings | ||
| 10.02. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Achieves Second WHO INN Milestone, Strengthening Global Regulatory Positioning Across Expanding Cell Therapy Pipeline | 2 | GlobeNewswire (USA) | ||
| 10.02. | Creative Medical receives WHO designation for second cell therapy | 3 | Investing.com | ||
| 13.01. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Reaches Major Clinical Inflection Point with Positive Interim Data from ADAPT Trial and CELZ-201 (Olastrocel) in the Treatment of Chronic Lower Back Pain | 359 | GlobeNewswire (Europe) | PHOENIX, Jan. 13, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 06.01. | Creative Medical Technology Holdings, Inc.: Creative Medical Technology Holdings Receives Regulatory Approval for BioDefense Burn Pit Initiative | 231 | GlobeNewswire (Europe) | PHOENIX, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) ("Creative Medical" or the "Company"), a clinical-stage biotechnology company advancing regenerative... ► Artikel lesen | |
| 17.12.25 | Creative Medical Technology Holdings, Inc. Completes Enrollment in FDA-Cleared ADAPT Trial for CELZ-201-Olastrocel, Marking Major Clinical Inflection Point | 245 | GlobeNewswire (Europe) | PHOENIX, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company advancing regenerative medicine solutions, today announced... ► Artikel lesen |
1 2 Weiter >>
22 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| APOGEE THERAPEUTICS | 134,27 | -0,01 % | Laufende Fusionskontrollverfahren: AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USA | Datum der Anmeldung:07.07.2026Aktenzeichen:B3-76/26Unternehmen:AbbVie Inc., North Chicago/Illinois/USA; Erwerb von Anteilen an und alleiniger Kontrolle über die Apogee Therapeutics, Inc., San Francisco/CA/USAProduktmärkte:Biotechnologie... ► Artikel lesen | |
| COGENT BIOSCIENCES | 39,320 | +0,05 % | Cogent Biosciences, Inc.: Cogent Biosciences Announces Submission of New Drug Application (NDA) for Bezuclastinib in Advanced Systemic Mastocytosis (AdvSM) | Submission based on results of APEX pivotal trial which demonstrated bezuclastinib objective response rate (CR+CRh+PR+CI) of 65% per mIWG criteria and 81% ORR per PPR criteria with a well-tolerated... ► Artikel lesen | |
| ANNEXON | 6,510 | +0,15 % | Needham raises Annexon Biosciences stock price target to $25 on trial | ||
| ERNEXA THERAPEUTICS | 6,670 | -0,89 % | Ernexa Therapeutics Inc.: Ernexa Therapeutics Receives Independent Validation of ERNA-101 with Complete Tumor Clearance and Durable Survival in Ovarian Cancer Models Ahead of Planned Clinical Entry | Independent CRO Successfully Reproduces ERNA-101 Combination Data in Larger Preclinical Study, Significantly Strengthening Confidence as Company Advances Toward IND ERNA-101 Plus Anti-PD-1 Achieved... ► Artikel lesen | |
| PRAXIS PRECISION MEDICINES | 318,22 | -0,06 % | Piper Sandler reiterates Praxis Precision Medicines stock rating | ||
| TYRA BIOSCIENCES | 32,380 | 0,00 % | Tyra Biosciences Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Highlights | - Launched "dabogratinib 3x3" strategy to pursue 3 late-stage clinical studies in LG-UTUC, IR NMIBC and ACH, 3 potential blockbuster indications -
- Interim Ph2... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 3,305 | -0,15 % | Recursion Pharmaceuticals: Recursion Reports First Quarter Financial Results and Provides Business Update | Multiple milestones achieved or on track across wholly owned and partnered programs REC-1245 (RBM39 degrader): Early clinical data in solid tumors demonstrate a well-tolerated safety profile and predictable... ► Artikel lesen | |
| ABSCI | 9,765 | +0,05 % | Absci Corporation: Absci to Report Business Updates and Second Quarter 2026 Financial and Operating Results on August 11, 2026 | ||
| ARCUTIS BIOTHERAPEUTICS | 27,770 | -0,04 % | Arcutis Biotherapeutics, Inc.: FDA Accepts Supplemental New Drug Application for Arcutis' ZORYVE (roflumilast) Cream 0.05% for the Treatment of Mild to Moderate Atopic Dermatitis in Infants Down to 3 Months | FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of February 23, 2027Application supported by positive results from Phase 2 open-label INTEGUMENT-INFANT study and Phase 1 open-label... ► Artikel lesen | |
| DYNE THERAPEUTICS | 24,000 | +0,04 % | Dyne Therapeutics, Inc.: Dyne Therapeutics Announces Expanded Debt Facility of Up To $400 Million with Hercules Capital, Inc. | - Up to $125 million in additional borrowing capacity provides further strategic flexibility - - $50 million of additional capacity funded at amendment closing - WALTHAM, Mass., June 17, 2026 (GLOBE... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 40,850 | +0,05 % | Servier completes the acquisition of Edgewise Therapeutics' Muscular Dystrophy Business | Acquisition supports Servier's strategic ambition in rare neurology with sevasemten, a late-stage investigational treatment for Becker and Duchenne muscular dystrophies. The acquired asset... ► Artikel lesen | |
| RELAY THERAPEUTICS | 19,520 | +0,05 % | Relay Therapeutics, Inc.: Relay Therapeutics Announces Pricing of Public Offering of Common Stock | CAMBRIDGE, Mass., May 20, 2026 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage, small molecule precision medicine company developing potentially life-changing therapies... ► Artikel lesen | |
| SHATTUCK LABS | 6,780 | +0,15 % | Shattuck Labs Announces Pricing Of 10.88 Mln Shares Public Offering At $4/Shr | WASHINGTON (dpa-AFX) - Shattuck Labs, Inc. (STTK), a clinical-stage biotechnology company, on Wednesday revealed the pricing of its earlier announced public offering of 10.88 million shares... ► Artikel lesen | |
| ENLIVEN THERAPEUTICS | 53,19 | +0,06 % | Enliven Therapeutics, Inc.: Enliven Therapeutics Announces Pricing of Upsized Public Offering of Common Stock and Pre-Funded Warrants | BURLINGAME, Calif., June 11, 2026 /PRNewswire/ -- Enliven Therapeutics, Inc. (Enliven or the Company) (Nasdaq: ELVN), a clinical-stage biopharmaceutical company... ► Artikel lesen | |
| TAYSHA GENE THERAPIES | 6,200 | +0,16 % | Taysha Gene Therapies, Inc.: Taysha Gene Therapies Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants | DALLAS, June 24, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA) (Taysha or the Company), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based... ► Artikel lesen |
Das Unternehmen CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,010 (-1,22 %) liegt der Kurs bei 0,812 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CREATIVE MEDICAL TECHNOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.